These data suggest that expression of constitutively activated BRAF uniquely predicts sensitivity to MEK inhibition compared to tumours with RAS mutations, perhaps owing to RAS-mediated activation of signalling molecules not in the linear RAS–RAF cascade (Figure 1). The gene discussed is RAF1; the disease is neoplasm.